ES2168302T3 - Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e. - Google Patents

Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.

Info

Publication number
ES2168302T3
ES2168302T3 ES94920705T ES94920705T ES2168302T3 ES 2168302 T3 ES2168302 T3 ES 2168302T3 ES 94920705 T ES94920705 T ES 94920705T ES 94920705 T ES94920705 T ES 94920705T ES 2168302 T3 ES2168302 T3 ES 2168302T3
Authority
ES
Spain
Prior art keywords
serotype
botulin toxin
neuromuscular
disorders
states
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94920705T
Other languages
English (en)
Inventor
K Roger Aoki
Michael W Grayston
Steven R Carlson
Judith M Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2168302T3 publication Critical patent/ES2168302T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UN METODO DE TRATAMIENTO DE UN PACIENTE QUE SUFRE DE UNA ENFERMEDAD, DESORDEN O CONDICION INCLUYE LA ADMINISTRACION AL PACIENTE DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE TOXINA DE BOTULINA DE UN SEROTIPO SELECCIONADO HASTA QUE EL PACIENTE EXPERIMENTE PERDIDA DE RESPUESTA CLINICA A LA TOXINA DE BOTULINA ADMINISTRADA Y POSTERIORMENTE LA ADMINISTRACION AL PACIENTE DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE OTRA TOXINA DE BOTULINA DE UN SEROTIPO DIFERENTE.
ES94920705T 1993-06-10 1994-06-07 Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e. Expired - Lifetime ES2168302T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7504893A 1993-06-10 1993-06-10

Publications (1)

Publication Number Publication Date
ES2168302T3 true ES2168302T3 (es) 2002-06-16

Family

ID=22123211

Family Applications (5)

Application Number Title Priority Date Filing Date
ES03018639T Expired - Lifetime ES2329232T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente.
ES94920705T Expired - Lifetime ES2168302T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
ES04027108T Expired - Lifetime ES2335281T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente.
ES04027109T Expired - Lifetime ES2335662T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con diferentes serotipos de botulinum.
ES08002883T Expired - Lifetime ES2341140T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con un seropositivo botulinico diferente.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES03018639T Expired - Lifetime ES2329232T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente.

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES04027108T Expired - Lifetime ES2335281T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente.
ES04027109T Expired - Lifetime ES2335662T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con diferentes serotipos de botulinum.
ES08002883T Expired - Lifetime ES2341140T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con un seropositivo botulinico diferente.

Country Status (8)

Country Link
US (3) US6872397B2 (es)
EP (7) EP0702561B1 (es)
JP (4) JPH08511536A (es)
AU (1) AU689115B2 (es)
CA (3) CA2332406C (es)
DE (6) DE122009000066I2 (es)
ES (5) ES2329232T3 (es)
WO (1) WO1994028922A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
DE122009000066I2 (de) * 1993-06-10 2010-12-30 Allergan Inc Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
DE69428813T2 (de) * 1993-12-28 2002-04-04 Allergan Sales Inc Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
EP0773788B1 (en) * 1995-06-06 2003-05-07 L. Bruce Pearce Improved compositions and methods for chemodenervation using neurotoxins
EP1053014A4 (en) 1998-01-26 2004-11-10 Univ Massachusetts BIOLOGICALLY ACTIVE HEMAGGLUTININE TYPE A i (STRIDIUM BOTULINUM) AND METHOD FOR ITS USE
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
WO2004031355A2 (en) * 2002-10-01 2004-04-15 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
BRPI0408114A (pt) * 2003-03-06 2006-03-01 Botulinum Toxin Res Ass Inc tratamento de calázio crÈnico e hordéolo com toxina botulinìca
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US20080274480A1 (en) * 2004-08-04 2008-11-06 Allergan, Inc. Botulinum Toxin Type a Immunoresistant Assay
DE602005011458D1 (de) 2004-09-01 2009-01-15 Allergan Inc Abbaubare clostridientoxine
AU2006227816B2 (en) * 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
CA2605160A1 (en) 2005-04-05 2006-10-05 Allergan, Inc. Clostridial toxin activity assays
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US9511210B2 (en) * 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US7608275B2 (en) 2005-07-22 2009-10-27 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
EP2001902B1 (en) 2006-03-14 2013-03-27 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US20110033431A1 (en) * 2008-03-31 2011-02-10 The Chemo-Sero-Therapeutic Research Institute Type a2 botulinum toxin preparation
KR101719824B1 (ko) 2008-05-09 2017-04-04 호라이라 인코포레이티드 기관지나무 치료용 시스템, 어셈블리 및 방법
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
EP2926757B1 (en) 2009-10-27 2023-01-25 Nuvaira, Inc. Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
AU2010319477A1 (en) 2009-11-11 2012-05-24 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
CA2869599C (en) 2012-04-13 2021-07-27 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
JP7118055B2 (ja) 2016-09-29 2022-08-15 イプセン バイオファーム リミテッド ハイブリッド神経毒
EP3758611B1 (en) 2018-02-26 2024-07-24 Ipsen Biopharm Limited Ultrasound apparatus to guide injection of non-cytotoxic protease
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2373454A (en) * 1943-07-09 1945-04-10 Squibb & Sons Inc Method of preparing tetanus toxin
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US3132995A (en) * 1961-10-20 1964-05-12 Carter Prod Inc Endotoxin fractions and method for producing same
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5401243A (en) 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5183462A (en) 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
FR2692475B1 (fr) 1992-06-19 2000-04-21 Montpellier Chirurgie Prothese totale du genou.
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
DE122009000066I2 (de) 1993-06-10 2010-12-30 Allergan Inc Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69428813T2 (de) 1993-12-28 2002-04-04 Allergan Sales Inc Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz

Also Published As

Publication number Publication date
DE69435284D1 (de) 2010-04-29
CA2164866C (en) 2001-09-11
WO1994028922A1 (en) 1994-12-22
ES2341140T3 (es) 2010-06-15
EP1374886A3 (en) 2004-02-11
DE69429619T2 (de) 2002-09-12
EP1166793A1 (en) 2002-01-02
DE69435253D1 (de) 2009-12-31
EP1941898A3 (en) 2008-11-05
ES2329232T3 (es) 2009-11-24
CA2310845A1 (en) 1994-12-22
JPH08511536A (ja) 1996-12-03
EP1099445A3 (en) 2001-09-05
JP2011256193A (ja) 2011-12-22
EP0702561A1 (en) 1996-03-27
DE122009000066I1 (de) 2010-02-04
DE69435254D1 (de) 2009-12-31
EP1508336A1 (en) 2005-02-23
EP0702561B1 (en) 2002-01-09
EP1941898A2 (en) 2008-07-09
EP1099445A2 (en) 2001-05-16
JP2010111703A (ja) 2010-05-20
ES2335281T3 (es) 2010-03-24
US20010012833A1 (en) 2001-08-09
EP1508336B1 (en) 2009-11-18
US20050129716A1 (en) 2005-06-16
DE122009000066I2 (de) 2010-12-30
HK1061648A1 (en) 2004-09-30
DE69429619D1 (de) 2002-02-14
EP1374886A2 (en) 2004-01-02
EP1512411B1 (en) 2009-11-18
AU689115B2 (en) 1998-03-26
ES2335662T3 (es) 2010-03-31
US6872397B2 (en) 2005-03-29
EP1374886B1 (en) 2009-09-02
DE69435235D1 (de) 2009-10-15
US20020010138A1 (en) 2002-01-24
JP2005281317A (ja) 2005-10-13
EP1941898B1 (en) 2010-03-17
EP1512411A1 (en) 2005-03-09
CA2332406C (en) 2005-01-04
CA2310845C (en) 2001-05-15
CA2164866A1 (en) 1994-12-22
AU7087894A (en) 1995-01-03
CA2332406A1 (en) 1994-12-22

Similar Documents

Publication Publication Date Title
ES2168302T3 (es) Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
ES2194025T3 (es) Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
PT646012E (pt) Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
EP0850648A3 (en) Combination of thrombolytically active proteins and anticoagulants and uses thereof
WO1994028922B1 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
RU95106651A (ru) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
PT998287E (pt) Utilizacao de levobupivacaina
HRP920834B1 (en) A method for producing an administration and/or dosage form for pharmaceutical active substances using a printing method
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
FI942660L (fi) Actinoplanes sp:stä olevia lipopeptidejä, joilla on farmakologista vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
EP0286802A3 (en) Use of ofloxacin in treating or preventing locally periodontal disease
FI950649A7 (fi) Substituoidut sykloheksanoliesterit, niiden käyttö sairauksien hoitamiseksi ja farmaseuttiset valmisteet
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
SE9101341D0 (sv) New medicinal use
UA10335A (uk) Спосіб корекції порушеhь обміhу кальцію у хворих hа сиhдром рейтера хламідійhої етіології
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
UA12425A (uk) Спосіб лікуваhhя субарахhоідальhих крововиливів
UA10259A (uk) Протинабряковий лікарський препарат "нейрополіосм"

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 702561

Country of ref document: ES